文献速递药物不良反应与药物警戒

药物安全性Meta分析中数据来源对结论的影响

Diverging Conclusions from the Same Meta-Analysis in Drug Safety: Source of Data (Primary Versus Secondary) Takes a Toll.
PubMed 文献 · Drug Saf · 2017-01-01

该研究评估了在药物安全性Meta分析中,将暴露数据来源(原始数据与二次数据)作为异质性来源进行分层分析对结论的影响。研究选取了2013至2015年发表的4篇Meta分析,按数据来源分层后结果发生显著改变,提示忽略数据来源可能导致误导性结论。

要点

  • 药物安全性Meta分析中,原始数据与二次数据来源可导致结论显著不同。
  • 按数据来源分层分析可改变原Meta分析的合并效应估计。
  • 评估数据来源异质性对避免误导性结论至关重要。

核心结论

  • 按数据来源分层后,药物安全性Meta分析的结论发生显著改变。
  • 探索数据来源(原始或二次)作为异质性来源对避免误导性结论至关重要。

研究设计与样本

  • 选取2013至2015年发表的Meta分析,其暴露为常用非处方药摄入,结局具有短潜伏期和诱导期。
  • 按数据来源(原始数据与二次数据)分层,比较新结果与原Meta分析结果。
  • 共纳入4篇符合标准的Meta分析。

主要发现

  • SSRIs与上消化道出血:原始估计OR=1.71(95%CI 1.44-2.04),原始数据OR=1.19(95%CI 0.90-1.58),二次数据OR=1.81(95%CI 1.50-2.17)。
  • PPIs与心脏事件:原始估计HR=1.35(95%CI 1.18-1.54),原始数据HR=1.05(95%CI 0.87-1.26),二次数据HR=1.43(95%CI 1.23-1.66)。
  • 非阿司匹林NSAIDs与心肌梗死:原始估计RR=1.08(95%CI 0.95-1.22),原始数据RR=0.57(95%CI 0.34-0.96),二次数据RR=1.15(95%CI 1.03-1.28)。
  • 孕期对乙酰氨基酚与儿童哮喘:原始估计OR=1.32(95%CI 1.14-1.52),原始数据OR=1.23(95%CI 1.06-1.42),二次数据OR=1.53(95%CI 1.33-1.75)。

临床怎么用

  • 在解读药物安全性Meta分析时,应关注原始数据与二次数据来源对结果的影响。
  • 临床药师可建议在敏感性或亚组分析中按数据来源分层,以评估结论稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Meta-analyses of observational studies represent an important tool for assessing efficacy and safety in the pharmacoepidemiologic field. The data from the individual studies are either primary (i.e., collected through interviews or self-administered questionnaires) or secondary (i.e., collected from databases that were established for other purposes). So far, the origin of the data (primary vs. secondary) has not been systematically assessed as a source of heterogeneity in pharmacoepidemiologic meta-analyses. OBJECTIVE: The aim was to assess the impact of considering the source of exposure data as a criterion in sensitivity and subgroup analysis on the conclusions of drug safety meta-analyses. METHODS: We selected meta-analyses published between 2013 and 2015 in which the intake of frequently used over-the-counter medicines was either the main exposure or a concomitant treatment and the outcome had short latency and induction periods. We stratified the results by origin of data (primary vs. secondary) and compared the new results to those presented originally in the meta-analyses. RESULTS: We used four meta-analyses that fulfilled our criteria of inclusion. The results were selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: original estimate odds ratio (OR) = 1.71 [95% confidence interval (CI) 1.44-2.04], OR primary data = 1.19 (95% CI 0.90-1.58), OR secondary data = 1.81 (95% CI 1.50-2.17); proton pump inhibitors and cardiac events: original estimate hazard ratio (HR) = 1.35 (95% CI 1.18-1.54), HR primary data = 1.05 (95% CI 0.87-1.26), HR secondary data = 1.43 (95% CI 1.23-1.66); non-aspirin non-steroidal anti-inflammatory drugs and myocardial infarction: original estimate risk ratio (RR) = 1.08 (95% CI 0.95-1.22), RR primary data = 0.57 (95% CI 0.34-0.96), RR secondary data = 1.15 (95% CI 1.03-1.28); paracetamol during pregnancy and childhood asthma: original estimate OR = 1.32 (95% CI 1.14-1.52), OR primary data = 1.23 (95% CI 1.06-1.42), OR secondary data = 1.53 (95% CI 1.33-1.75). CONCLUSIONS: The results after stratification are considerably modified. It is crucial to explore the origin of the data, either primary or secondary, as a source of heterogeneity in pharmacoepidemiologic meta-analyses to avoid misleading conclusions.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Prada-Ramallal G, Takkouche B, Figueiras A, et al. Diverging Conclusions from the Same Meta-Analysis in Drug Safety: Source of Data (Primary Versus Secondary) Takes a Toll. Drug Saf. 2017. PMID: 28005253. doi:10.1007/s40264-016-0492-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。